Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 2
1971 4
1972 2
1973 4
1974 2
1975 2
1976 6
1977 3
1978 2
1979 6
1980 5
1981 7
1982 3
1983 6
1984 10
1985 10
1986 7
1987 18
1988 40
1989 67
1990 62
1991 56
1992 77
1993 75
1994 90
1995 202
1996 290
1997 290
1998 358
1999 307
2000 309
2001 348
2002 354
2003 381
2004 377
2005 359
2006 381
2007 332
2008 451
2009 367
2010 408
2011 427
2012 475
2013 516
2014 565
2015 541
2016 586
2017 570
2018 503
2019 240
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

9,735 results
Results by year
Filters applied: . Clear all
Page 1
Proteasome-associated deubiquitinases and cancer
Mofers A, et al. Cancer Metastasis Rev 2017 - Review. PMID 29134486 Free PMC article.
Spurred on by this success, promising novel inhibitors of the UPS have entered development, targeting the 20S as well as regulatory 19S subunit and inhibitors of deubiquitinating and ubiquitin ligase enzymes. In this review, we outline the manner in which deregulation of the UPS can cause cancer to develop, current clinical application of proteasome inhibitors, and the (pre-)clinical development of novel inhibitors of the UPS....
Spurred on by this success, promising novel inhibitors of the UPS have entered development, targeting the 20S as well as regulatory 1 …
Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature
Brown T, et al. J Clin Hypertens (Greenwich) 2017 - Review. PMID 28994183 Free article.
According to the National Health and Nutrition Examination Survey 2012, one third of antihypertensive prescriptions in the United States in the past decade were for angiotensin-converting enzyme inhibitors (ACEIs). ...
According to the National Health and Nutrition Examination Survey 2012, one third of antihypertensive prescriptions in the United States in …
Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis.
Pedersen NC, et al. J Feline Med Surg 2018. PMID 28901812 Free PMC article.
Objectives The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP). ...
Objectives The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various f …
Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?
Mikler J, et al. Pediatr Cardiol 2019 - Review. PMID 31327027
This condition is usually treated with heparin or low molecular weight heparins which require parenteral administration and, in case of unfractionated heparin, also frequent laboratory monitoring and dose adjustment. Direct oral anticoagulants (DOACs)-direct thrombin inhibitor dabigatran, and direct oral factor Xa inhibitors rivaroxaban, apixaban, and edoxaban-are currently frequently used for the prevention and treatment of VTE in adult population. ...
This condition is usually treated with heparin or low molecular weight heparins which require parenteral administration and, in case …
Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis
Ebner M, et al. J Am Heart Assoc 2018 - Clinical Trial. PMID 30371316 Free PMC article.
Methods and Results In 481 samples obtained from 96 patients enrolled at a single center, DOAC concentrations were measured using Hemoclot direct thrombin inhibitor assay, Biophen direct thrombin inhibitor assay or ecarin clotting time for dabigatran, chromogenic anti-Xa assay ( AXA ) for factor Xa inhibitors (rivaroxaban, apixaban) and ultraperformance liquid chromatography-tandem mass spectrometry as reference. ...
Methods and Results In 481 samples obtained from 96 patients enrolled at a single center, DOAC concentrations were measured using Hemoclot d …
Drug interactions with new oral anticoagulants in elderly patients
Stöllberger C. Expert Rev Clin Pharmacol 2017 - Review. PMID 28825849
Dabigatran is the only NOAC interacting with proton-pump-inhibitors. Expert commentary: Dabigatran was the first NOAC approved, so it is not possible to determine whether the higher number of reports about DDIs with dabigatran compared with other NOACs is due to a higher rate of DDIs or to the length of time during which this drug has been in use. ...
Dabigatran is the only NOAC interacting with proton-pump-inhibitors. Expert commentary: Dabigatran was the first NOAC approved, so it …
Managing complications of hypertension in aortic valve stenosis patients
Saeed S and Gerdts E. Expert Rev Cardiovasc Ther 2018 - Review. PMID 30311814
Data from registries and post hoc analyses from outcome studies in AS suggest that treatment with angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and β-blockers, respectively, is safe and associated with improved survival and reduced CV events in these patients. ...
Data from registries and post hoc analyses from outcome studies in AS suggest that treatment with angiotensin converting enzyme inhibitor
Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.
Zuo K, et al. Cancer Metastasis Rev 2019 - Review. PMID 31471691
Matriptase is a type II transmembrane serine protease, which has been suggested to play critical roles in numerous pathways of biological developments. ...Thus far, inhibitors of matriptase have been developed as potential anti-cancer agents, which include small-molecule inhibitors, peptide-based inhibitors, and monoclonal antibodies. ...
Matriptase is a type II transmembrane serine protease, which has been suggested to play critical roles in numerous pathways of biolog …
9,735 results
Jump to page
Feedback